{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:51:38Z","timestamp":1791575498164,"version":"4.3.4"},"reference-count":85,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The impressive advances in the knowledge of biomarkers and molecular targets has enabled significant progress in drug therapy for crucial diseases such as cancer. Specific areas of pharmacology have contributed to these therapeutic outcomes\u2014mainly targeted therapy, immunomodulatory therapy, and gene therapy. This review focuses on the pharmacological profiles of these therapeutic classes and intends, on the one hand, to provide a systematic definition and, on the other, to highlight some aspects related to pharmacovigilance, namely the monitoring of safety and the identification of potential toxicities and adverse drug reactions. Although clinicians often consider pharmacovigilance a non-priority area, it highlights the risk\/benefit ratio, an essential factor, especially for these advanced therapies, which represent the most innovative and promising horizon in oncology.<\/jats:p>","DOI":"10.3390\/ijms23063012","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T20:19:10Z","timestamp":1646943550000},"page":"3012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5171-7499","authenticated-orcid":false,"given":"Sabrina","family":"Orzetti","sequence":"first","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"},{"name":"Department of Hospital Pharmacy, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7590-7043","authenticated-orcid":false,"given":"Federica","family":"Tommasi","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bertola","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8921-3093","authenticated-orcid":false,"given":"Giorgia","family":"Bortolin","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-3370","authenticated-orcid":false,"given":"Elisabetta","family":"Caccin","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0656-7521","authenticated-orcid":false,"given":"Sara","family":"Cecco","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-5433","authenticated-orcid":false,"given":"Emanuela","family":"Ferrarin","sequence":"additional","affiliation":[{"name":"Scientific and Patients Library of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-7783","authenticated-orcid":false,"given":"Elisa","family":"Giacomin","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-7120","authenticated-orcid":false,"given":"Paolo","family":"Baldo","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit of the \u201cCentro di Riferimento Oncologico (CRO) di Aviano IRCCS\u201d, Via F. Gallini, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"ref_1","unstructured":"Associazione Italiana di Oncologia Medica (AIOM), and Associazione Italiana Registri Tumori (AIRTUM) (2019). Report nazionale. I Numeri del Cancro in Italia 2019, Intermedia Editore."},{"key":"ref_2","unstructured":"MeSH Browser, U.S. (2021, July 21). National Library of Medicine, Available online: https:\/\/meshb.nlm.nih.gov\/search."},{"key":"ref_3","first-page":"1","article-title":"The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism","volume":"76","author":"Amanpour","year":"2021","journal-title":"Arch. Razi. Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liu, J., Pandya, P., and Afshar, S. (2021). Therapeutic Advances in Oncology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042008"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Fu, Z., and Xiang, J. (2020). Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082793"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Crowther, M.D., Svane, I.M., and Met, \u00d6. (2020). T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road. Cells, 9.","DOI":"10.3390\/cells9071588"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"118134","DOI":"10.1016\/j.lfs.2020.118134","article-title":"Combinatorial drug therapy in cancer-New insights","volume":"258","author":"Bhatia","year":"2020","journal-title":"Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1749-6632.1952.tb39969.x","article-title":"Viruses with oncolytic properties and their adaptation to tumors","volume":"54","author":"Moore","year":"1952","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., and Franci, G. (2021). Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13112761"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","article-title":"The Oncolytic Virus in Cancer Diagnosis and Treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yano, S., Tazawa, H., Kishimoto, H., Kagawa, S., Fujiwara, T., and Hoffman, R.M. (2021). Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020879"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7150\/thno.3724","article-title":"Theranostic potential of oncolytic vaccinia virus","volume":"2","author":"Rojas","year":"2012","journal-title":"Theranostics"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chulpanova, D.S., Solovyeva, V.V., Kitaeva, K.V., Dunham, S.P., Khaiboullina, S.F., and Rizvanov, A.A. (2018). Recombinant Viruses for Cancer Therapy. Biomedicines, 6.","DOI":"10.3390\/biomedicines6040094"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: Challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yu, W.L., and Hua, Z.C. (2019). Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid malignancies: Efficacy and safety\u2014a systematic review with meta-analysis. Cancers, 11.","DOI":"10.3390\/cancers11010047"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/156800911793743664","article-title":"Cancer vaccines in phase II\/III clinical trials: State of the art and future perspectives","volume":"11","author":"Cecco","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Donninger, H., Li, C., and Yaddanapudi, K. (2021). Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. Vaccines, 9.","DOI":"10.3390\/vaccines9060668"},{"key":"ref_22","first-page":"269","article-title":"Vaccines Through Centuries: Major Cornerstones of Global Health","volume":"3","author":"Chams","year":"2015","journal-title":"Front. Public Health"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Filin, I.Y., Solovyeva, V.V., Kitaeva, K.V., Rutland, C.S., and Rizvanov, A.A. (2020). Current Trends in Cancer Immunotherapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120621"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chaurasiya, S., Fong, Y., and Warner, S.G. (2021). Oncolytic Virotherapy for Cancer: Clinical Experience. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040419"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Xiong, H., Veedu, R.N., and Diermeier, S.D. (2021). Recent Advances in Oligonucleotide Therapeutics in Oncology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073295"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Adachi, H., Hengesbach, M., Yu, Y.T., and Morais, P. (2021). From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050550"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Roy, D., Pascher, A., Juratli, M.A., and Sporn, J.C. (2021). The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115601"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2000063","DOI":"10.1002\/sstr.202000063","article-title":"Liquid biopsy: Application in Early Diagnosis and Monitoring of Cancer","volume":"1","author":"Junjie","year":"2020","journal-title":"Small Struct."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Lai, B.S., and Juhas, M. (2019). Recent Advances in Aptamer Discovery and Applications. Molecules, 24.","DOI":"10.3390\/molecules24050941"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13181-021-00835-6","article-title":"A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses","volume":"18","author":"Chhabra","year":"2022","journal-title":"J. Med. Toxicol."},{"key":"ref_32","unstructured":"(2021, September 24). Eudravigilance European Database of Adverse Drug Reactions Reports. Available online: www.adrreports.eu."},{"key":"ref_33","unstructured":"(2021, September 22). OPEN Vigil FDA v1.0.2. Available online: https:\/\/openvigil.pharmacology.uni-kiel.de\/openvigilfda.php."},{"key":"ref_34","unstructured":"(2021, September 27). Lexicomp\u00ae Database. Available online: http:\/\/online.lexi.com\/lco\/action\/home;jsessionid=DC1FA0C3E42571B7BA802A0F2E860F57."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and Biosafety of Oncolytic Virotherapy","volume":"16","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions Related to CAR-T Cell Therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ehf2.12589","article-title":"Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis","volume":"7","author":"Michel","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Semeraro, G.C., Cipolla, C.M., and Cardinale, D.M. (2021). Role of Cardiac Biomarkers in Cancer Patients. Cancers, 13.","DOI":"10.3390\/cancers13215426"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","article-title":"Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma","volume":"18","author":"Panowski","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit. Care."},{"key":"ref_50","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tay, B.Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J.W., Panizza, B.J., Frazer, I.H., and Cruz, J.L.G. (2021). Evolution of Cancer Vaccines\u2014Challenges, Achievements, and Future Directions. Vaccines, 9.","DOI":"10.3390\/vaccines9050535"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial","volume":"15","author":"Mittendorf","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"8","author":"Hollingsworth","year":"2019","journal-title":"NPJ Vaccines."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","year":"2018","journal-title":"Europ. J. Pharmacol."},{"key":"ref_55","first-page":"311","article-title":"Targeted Therapies: A New Generation of Cancer Treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am. Fam. Physician"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bcpt.12313","article-title":"Novel points of attack for targeted cancer therapy","volume":"116","author":"Rosland","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3322\/caac.21600","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park","year":"2020","journal-title":"Cancer J. Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s43441-021-00315-7","article-title":"Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials","volume":"55","author":"Lu","year":"2021","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_59","first-page":"855","article-title":"Progress in cancer chemiotherapy with special stress on molecular-targeted therapy","volume":"40","author":"Saijo","year":"2010","journal-title":"Pjn. J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermical growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Sem. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody Therapeutics in Cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: Harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"JCI"},{"key":"ref_63","unstructured":"Banca Dati CODIFA (2021). L\u2019informatore Farmaceutico, Ediser. [80rd ed.]."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00259-017-3695-3","article-title":"Molecularly targeted therapies in cancer: A guide for the nuclear medicine physician","volume":"44","author":"Lheureux","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung Cancer using a Clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-019-05261-5","article-title":"Management of toxicities associated with targeted terapie for HR-positive metastatic breast cancer: A multidisciplinary approach is the key to success","volume":"176","author":"Cazzaniga","year":"2019","journal-title":"Breast Cancer Res. Tr."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00520-016-3419-4","article-title":"Dermatologic events from EGFR inhibitors: The issue of the missing patient voice","volume":"25","author":"Tischer","year":"2017","journal-title":"Supp. Care Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/cam4.302","article-title":"Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: A medical chart review across ten centers in five European countries","volume":"3","author":"Porta","year":"2014","journal-title":"Cancer Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Du, R., Wang, X., Ma, L., Larcher, L.M., Tang, H., Zhou, H., Chen, C., and Wang, T. (2021). Adverse reactions of targeted therapy in cancer patients: A retrospective study of hospital medical data in China. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07946-x"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1568009617666170206111609","article-title":"Oncolytic viruses: The best is yet to come","volume":"18","author":"Lemay","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bcp.14159","article-title":"Serious adverse effects occuring after chemotherapy: A general cancer registry-based incidence survey","volume":"86","author":"Ingrand","year":"2020","journal-title":"B. J. Clin. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine Therapies for Cancer: Then and Now","volume":"16","author":"Morse","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_74","unstructured":"(2021, September 19). Home\u2013ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical Care Management of Toxicities Associated with Targeted Agents and Immunotherapies for Cancer","volume":"48","author":"Gutierrez","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drup.2012.10.003","article-title":"Understanding resistance to combination chemotherapy","volume":"15","author":"Pritchard","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Delou, J.M.A., Souza, A.S.O., Souza, L.C.M., and Borges, H.L. (2019). Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells., 30.","DOI":"10.3390\/cells8091013"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molmed.2018.12.009","article-title":"Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology","volume":"25","author":"Sabnis","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","article-title":"Overcoming Chemotherapy Resistance in SCLC","volume":"16","author":"Herzog","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Nedeljkovi\u0107, M., and Damjanovi\u0107, A. (2019). Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells, 22.","DOI":"10.3390\/cells8090957"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"821609","DOI":"10.3389\/fcell.2022.821609","article-title":"The Emerging Roles of Circular RNAs in the Chemoresistance of Gastrointestinal Cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_84","unstructured":"(2021, September 21). Pharmacovigilance Directive 2010\/84\/EU of the European Parliament and of the Council of 15 December 2010. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32010L0084&from=it."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s11096-018-0706-9","article-title":"Pharmacovigilance in oncology","volume":"40","author":"Baldo","year":"2018","journal-title":"Int J. Clin. Pharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:34:40Z","timestamp":1760135680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/6\/3012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":85,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23063012"],"URL":"https:\/\/doi.org\/10.3390\/ijms23063012","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]}}}